Rebecca G Boswell1, Marc N Potenza2, Carlos M Grilo3. 1. Yale School of Medicine, Department of Psychiatry, New Haven, CT, USA. Electronic address: rebecca.boswell@yale.edu. 2. Yale School of Medicine, Department of Psychiatry, New Haven, CT, USA; Connecticut Mental Health Center, New Haven, CT, USA; Connecticut Council on Problem Gambling, Wethersfield, CT, USA; Yale School of Medicine, Child Study Center, New Haven, CT, USA; Yale University, Department of Neuroscience, New Haven, CT, USA. 3. Yale School of Medicine, Department of Psychiatry, New Haven, CT, USA; Yale University, Department of Psychology, New Haven, CT, USA.
Abstract
PURPOSE: Emerging work indicates divergence in the neurobiologies of binge-eating disorder (BED) and obesity despite their frequent co-occurrence. This review highlights specific distinguishing aspects of BED, including elevated impulsivity and compulsivity possibly involving the mesocorticolimbic dopamine system, and discusses implications for differential therapeutics for BED. METHODS: This narrative review describes epidemiologic, clinical, genetic, and preclinical differences between BED and obesity. Subsequently, this review discusses human neuroimaging work reporting differences in executive functioning, reward processing, and emotion reactivity in BED compared with obesity. Finally, on the basis of the neurobiology of BED, this review identifies existing and new therapeutic agents that may be most promising given their specific targets based on putative mechanisms of action relevant specifically to BED. FINDINGS: BED is characterized by elevated impulsivity and compulsivity compared with obesity, which is reflected in divergent neurobiological characteristics and effective pharmacotherapies. Therapeutic agents that influence both reward and executive function systems may be especially effective for BED. IMPLICATIONS: Greater attention to impulsivity/compulsivity-related, reward-related, and emotion reactivity-related processes may enhance conceptualization and treatment approaches for patients with BED. Consideration of these distinguishing characteristics and processes could have implications for more targeted pharmacologic treatment research and interventions.
PURPOSE: Emerging work indicates divergence in the neurobiologies of binge-eating disorder (BED) and obesity despite their frequent co-occurrence. This review highlights specific distinguishing aspects of BED, including elevated impulsivity and compulsivity possibly involving the mesocorticolimbic dopamine system, and discusses implications for differential therapeutics for BED. METHODS: This narrative review describes epidemiologic, clinical, genetic, and preclinical differences between BED and obesity. Subsequently, this review discusses human neuroimaging work reporting differences in executive functioning, reward processing, and emotion reactivity in BED compared with obesity. Finally, on the basis of the neurobiology of BED, this review identifies existing and new therapeutic agents that may be most promising given their specific targets based on putative mechanisms of action relevant specifically to BED. FINDINGS: BED is characterized by elevated impulsivity and compulsivity compared with obesity, which is reflected in divergent neurobiological characteristics and effective pharmacotherapies. Therapeutic agents that influence both reward and executive function systems may be especially effective for BED. IMPLICATIONS: Greater attention to impulsivity/compulsivity-related, reward-related, and emotion reactivity-related processes may enhance conceptualization and treatment approaches for patients with BED. Consideration of these distinguishing characteristics and processes could have implications for more targeted pharmacologic treatment research and interventions.
Authors: Susan L McElroy; Anna I Guerdjikova; Thomas J Blom; Scott J Crow; Asli Memisoglu; Bernard L Silverman; Elliot W Ehrich Journal: Int J Eat Disord Date: 2013-02-05 Impact factor: 4.861
Authors: Stephanie S O'Malley; Rajita Sinha; Carlos M Grilo; Christy Capone; Conor K Farren; Sherry A McKee; Bruce J Rounsaville; Ran Wu Journal: Alcohol Clin Exp Res Date: 2007-04 Impact factor: 3.455
Authors: Palmiero Monteleone; Alfonso Tortorella; Eloisa Castaldo; Carmela Di Filippo; Mario Maj Journal: Psychiatr Genet Date: 2007-02 Impact factor: 2.458
Authors: Stephen A Wonderlich; Kathryn H Gordon; James E Mitchell; Ross D Crosby; Scott G Engel Journal: Int J Eat Disord Date: 2009-12 Impact factor: 4.861
Authors: Susan L McElroy; James Hudson; M Celeste Ferreira-Cornwell; Jana Radewonuk; Timothy Whitaker; Maria Gasior Journal: Neuropsychopharmacology Date: 2015-09-09 Impact factor: 7.853
Authors: Amanda Laque; Grant E Wagner; Alessandra Matzeu; Genna L De Ness; Tony M Kerr; Ayla M Carroll; Giordano de Guglielmo; Hermina Nedelescu; Matthew W Buczynski; Ann M Gregus; Thomas C Jhou; Eric P Zorrilla; Remi Martin-Fardon; Eisuke Koya; Robert C Ritter; Friedbert Weiss; Nobuyoshi Suto Journal: Br J Pharmacol Date: 2022-03-07 Impact factor: 9.473
Authors: Barbara Bȩtkowska-Korpała; Aleksandra Ćwiȩk; Bernadetta Izydorczyk; Anna Starowicz-Filip; Piotr Major Journal: Front Psychiatry Date: 2021-11-25 Impact factor: 4.157